Alexandra Gangi1, Jehan Shah2, Nathan Hatfield2, Johnna Smith2, Jennifer Sweeney2, Junsung Choi2, Ghassan El-Haddad2, Benjamin Biebel2, Nainesh Parikh2, Bulent Arslan3, Sarah E Hoffe4, Jessica M Frakes4, Gregory M Springett5, Daniel A Anaya5, Mokenge Malafa5, Dung-Tsa Chen6, Yunyun Chen6, Richard D Kim5, Ravi Shridhar7, Bela Kis8. 1. Diagnostic Imaging and Interventional Radiology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612; Department of Surgery, Cedars Sinai Medical Center, Los Angeles, California. 2. Diagnostic Imaging and Interventional Radiology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612. 3. Diagnostic Imaging and Interventional Radiology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612; Vascular and Interventional Radiology, Rush University Medical Center, Chicago, Illinois. 4. Radiation Oncology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612. 5. Gastrointestinal Oncology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612. 6. Biostatistics and Bioinformatics, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612. 7. Radiation Oncology, Florida Hospital Orlando, Orlando, Florida. 8. Diagnostic Imaging and Interventional Radiology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612. Electronic address: bela.kis@moffitt.org.
Abstract
PURPOSE: To evaluate the efficacy and safety of transarterial yttrium-90 glass microsphere radioembolization in patients with unresectable intrahepatic cholangiocarcinoma (ICC). MATERIALS AND METHODS: Retrospective review of 85 consecutive patients (41 men and 44 women; age, 73.4 ± 9.3 years) was performed. Survival data were analyzed by the Kaplan-Meier method, Cox regression models, and the log-rank test. RESULTS: Median overall survival (OS) from diagnosis was 21.4 months (95% confidence interval [CI]: 16.6-28.4); median OS from radioembolization was 12.0 months (95% CI: 8.0-15.2). Seven episodes of severe toxicity occurred. At 3 months, 6.2% of patients had partial response, 64.2% had stable disease, and 29.6% had progressive disease. Median OS from radioembolization was significantly longer in patients with Eastern Cooperative Oncology Group (ECOG) scores of 0 and 1 than patients with an ECOG score of 2 (18.5 vs 5.5 months, P = .0012), and median OS from radioembolization was significantly longer in patients with well-differentiated histology than patients with poorly differentiated histology (18.6 vs 9.7 months, P = .012). Patients with solitary tumors had significantly longer median OS from radioembolization than patients with multifocal disease (25 vs. 6.1 months, P = .006). The absence of extrahepatic metastasis was associated with significantly increased median OS (15.2 vs. 6.8 months, P = .003). Increased time from diagnosis to radioembolization was a negative predictor of OS. The morphology of the tumor (mass-forming or infiltrative, hyper- or hypo-enhancing) had no effect on survival. Post-treatment increased cancer antigen 19-9 level, increased international normalized ratio, decreased albumin, increased bilirubin, increased aspartate aminotransferase, and increased Model for End-Stage Liver Disease score were significant predictors of decreased OS. CONCLUSIONS: These data support the therapeutic role of radioembolization for the treatment of unresectable ICC with good efficacy and an acceptable safety profile.
PURPOSE: To evaluate the efficacy and safety of transarterial yttrium-90 glass microsphere radioembolization in patients with unresectable intrahepatic cholangiocarcinoma (ICC). MATERIALS AND METHODS: Retrospective review of 85 consecutive patients (41 men and 44 women; age, 73.4 ± 9.3 years) was performed. Survival data were analyzed by the Kaplan-Meier method, Cox regression models, and the log-rank test. RESULTS: Median overall survival (OS) from diagnosis was 21.4 months (95% confidence interval [CI]: 16.6-28.4); median OS from radioembolization was 12.0 months (95% CI: 8.0-15.2). Seven episodes of severe toxicity occurred. At 3 months, 6.2% of patients had partial response, 64.2% had stable disease, and 29.6% had progressive disease. Median OS from radioembolization was significantly longer in patients with Eastern Cooperative Oncology Group (ECOG) scores of 0 and 1 than patients with an ECOG score of 2 (18.5 vs 5.5 months, P = .0012), and median OS from radioembolization was significantly longer in patients with well-differentiated histology than patients with poorly differentiated histology (18.6 vs 9.7 months, P = .012). Patients with solitary tumors had significantly longer median OS from radioembolization than patients with multifocal disease (25 vs. 6.1 months, P = .006). The absence of extrahepatic metastasis was associated with significantly increased median OS (15.2 vs. 6.8 months, P = .003). Increased time from diagnosis to radioembolization was a negative predictor of OS. The morphology of the tumor (mass-forming or infiltrative, hyper- or hypo-enhancing) had no effect on survival. Post-treatment increased cancer antigen 19-9 level, increased international normalized ratio, decreased albumin, increased bilirubin, increased aspartate aminotransferase, and increased Model for End-Stage Liver Disease score were significant predictors of decreased OS. CONCLUSIONS: These data support the therapeutic role of radioembolization for the treatment of unresectable ICC with good efficacy and an acceptable safety profile.
Authors: K J Paprottka; F Schoeppe; M Ingrisch; J Rübenthaler; N N Sommer; E De Toni; H Ilhan; M Zacherl; A Todica; P M Paprottka Journal: Eur J Nucl Med Mol Imaging Date: 2017-02-14 Impact factor: 9.236
Authors: Zhongzhi Jia; Ricardo Paz-Fumagalli; Gregory Frey; David M Sella; J Mark McKinney; Weiping Wang Journal: J Cancer Res Clin Oncol Date: 2016-11-08 Impact factor: 4.553
Authors: Kerri A Simo; Laura E Halpin; Nicole M McBrier; Jacob A Hessey; Erin Baker; Samuel Ross; Ryan Z Swan; David A Iannitti; John B Martinie Journal: J Surg Oncol Date: 2016-01 Impact factor: 3.454
Authors: Charles E Ray; Anthony Edwards; Mitchell T Smith; Stephen Leong; Kimi Kondo; Matthew Gipson; Paul J Rochon; Rajan Gupta; Wells Messersmith; Tom Purcell; Janette Durham Journal: J Vasc Interv Radiol Date: 2013-05-28 Impact factor: 3.464
Authors: Shoaib Rafi; Sarat M Piduru; Bassel El-Rayes; John S Kauh; David A Kooby; Juan M Sarmiento; Hyun S Kim Journal: Cardiovasc Intervent Radiol Date: 2012-09-07 Impact factor: 2.740
Authors: Premsai Kumar; Rahul Mhaskar; Richard Kim; Daniel Anaya; Jessica Frakes; Sarah Hoffe; Junsung Choi; Bela Kis Journal: J Clin Exp Hepatol Date: 2022-04-01